Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

Status Completed

Clinical Trial Summary

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.

Clinical Trial Description

This will be a randomized double-blind interventional clinical study. This study proposes to evaluate the safety and immunogenicity of the investigational V184 live recombinant measles-vectored chikungunya vaccine delivered in 2 vaccinations, 28 days apart compared with saline placebo. After providing informed consent, individuals will be screened for eligibility including verification of previous exposure to chikungunya virus. They will then be randomized in a double-blind fashion to receive either V184 or saline placebo in a 1:1 ratio. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03807843
Study type	Interventional
Source	Themis Bioscience GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	July 16, 2019
Completion date	May 13, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02230163` - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins	Phase 1/Phase 2
Completed	`NCT04546724` - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults	Phase 3
Terminated	`NCT04455919` - Yoga for Chronic Chikungunya	N/A
Completed	`NCT03631719` - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting	`NCT04441905` - Phase 1 Study of SAR440894 vs Placebo	Phase 1
Completed	`NCT02562482` - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults	Phase 2
Completed	`NCT03028441` - Phase I Trial of Measles Vectored Chikungungya Vaccine	Phase 1
Completed	`NCT04909411` - Consequences of a Maternal-fetal Chikungunya Virus Infection	N/A
Completed	`NCT04786444` - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults	Phase 3
Completed	`NCT02553369` - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection	N/A
Recruiting	`NCT06106581` - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years	Phase 2
Recruiting	`NCT06007183` - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination	Phase 3
Completed	`NCT03635086` - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)	Phase 2
Completed	`NCT02861586` - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine	Phase 2
Active, not recruiting	`NCT04838444` - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)	Phase 3
Completed	`NCT03483961` - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults	Phase 2
Recruiting	`NCT06028841` - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)	Phase 3